HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets tough lymphoma in early trial
Disease control Recruiting nowThis study tests a drug called pidnarulex (CX-5461) in 50 people with aggressive B-cell lymphomas that have MYC gene changes. The goal is to find the safest dose and see if it can shrink tumors. Participants must have tried at least two prior treatments for some types or one for …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 22:37 UTC
-
New hope for aggressive lymphoma: targeted therapy plus chemo shows promise
Disease control Recruiting nowThis study tests whether a targeted drug (loncastuximab tesirine) plus rituximab, followed by standard chemotherapy, can improve outcomes for people with high-risk diffuse large B-cell lymphoma. About 24 adults with untreated, aggressive subtypes will receive this combination. Th…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New combo therapy offers hope for Hard-to-Treat leukemia
Disease control Recruiting nowThis study combines a targeted antibody-drug (inotuzumab ozogamicin) with low-intensity chemotherapy to treat adults with acute lymphoblastic leukemia (ALL). The goal is to find the best dose and see if the combination improves survival and remission rates. Participants include o…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New combo therapy aims to boost lymphoma treatment
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 participants will receive the combination as their first treatment. The goal is to see if the new mix can…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
Hope for lymphoma patients: new drug cocktail targets resistant cancer
Disease control Recruiting nowThis study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can shrink tumors or delay cancer return in people with large B-cell lymphoma that came back or didn't respond to prior treatment. About 227 adults wh…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
New hope for aggressive lymphoma: targeted drug combo under study
Disease control Recruiting nowThis early-phase study tests whether adding the targeted drug polatuzumab vedotin (with or without glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to see how well they tolerate …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 05, 2026 12:05 UTC